Table 1 Baseline demographics and characteristics
Variable | n = 906 |
|---|---|
Age, years | |
Mean ± SD | 39.10 ± 9.87 |
Median (range) | 39 (18–64) |
Gender, n (%) | |
Female | 579 (63.9) |
Male | 327 (36.1) |
Age at MS diagnosis, years | |
Mean ± SD | 30.52 ± 9.52 |
Median (range) | 29 (8–60) |
Duration of MS, yearsa | |
Mean ± SD | 8.56 ± 5.97 |
Median (range) | 7 (0–31) |
Number of relapses in previous year | |
Mean ± SD | 1.36 ± 0.67 |
Median (range) | 1 (1–5) |
EDSS score | |
Mean ± SD | 3.06 ± 1.65 |
Median (range) | 3.0 (0–6.5) |
Treatment history, n (%)b | |
Interferon beta-1a or -1b | 445 (49.1) |
Natalizumab | 220 (24.3) |
Glatiramer acetate | 186 (20.5) |
Azathioprine | 19 (2.1) |
Experimental drugs | 7 (0.8) |
Other | 4 (0.4) |
None | 25 (2.8) |